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5ABBREVIATIONS
AD: Alzheimer’s disease
AIF: Apoptosis-inducing factor
ALS: Amyotrophic lateral sclerosis
AMPA: ?-3-amino-hydroxy-5-methyl-4-isoxalolepropionate
ATP: Adenosine triphosphate
BBB: Blood-brain barrier
BDNF: Brain derived neurotrophic factor
BM: Basement membrane
CCA: Common carotid artery
CNS: Central nervous system
CNTF: Ciliary neurotrophic factor
CSPG: Chondroitin sulphate proteoglycan
DG: Dentate gyrus
DMEM: Dulbecco’s modified Eagle’s medium
DRG: Dorsal root ganglia
ECM: Extracellular matrix
EGF: Epithelial growth factor
FGF: Fibroblast growth factor
GAG: Glucosaminoglycan
GFAP: Glial fibrillary acidic protein
HEK: Human embryonic kidney
IGF-1: Insulin growth factor-1
KA: Kainic acid
KDI: Lysine, aspartic acid, isoleucine (Lys-Asp-Ile)
LIF: Leukemia inhibitory factor
MCAO: Middle cerebral artery occlusion
MS: Multiple sclerosis
NGF: Neural growth factor
NMDA: N-methyl-D-aspartate
NO: Nitric oxide
NT-3: Neurotrophin-3
NT-4/5: Neurotrophin-4/5
NT-6: Neurotrophin-6
NT-7: Neurotrophin-7
OPC: Oligodendrocyte precursor cells
PD: Parkinson’s disease
PNS: Peripheral nervous system
RT: Room temperature
SC: Spinal cord
SCI: Spinal cord injury
TGF: Transforming growth factor
TNF: Tumor necrosis factor
TNFR: Tumor necrosis factor receptor
tPA: tissue plasminogen activator
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7ABSTRACT
The regeneration capacity of the adult mammalian central nervous system (CNS) is lim-
ited. Following an insult to the CNS, many environmental factors inhibiting or stimulating
neuronal regrowth are activated. Several molecules including laminin have stimulating ef-
fects on CNS regeneration. Laminins are essential molecular constituents of all basement
membranes of the body. In the CNS, laminins are involved in developmental events, such
as neuronal migration and axon guidance, while in the adult CNS they participate in the
formation and maintenance of the blood-brain-barrier (BBB) and are involved in trauma
reactions of the CNS. Laminin-1 is a large glycoprotein and is composed from three disul-
fide-bonded subunits, ?1, ?1, and the ?1 chain. Many neurons express ?1 laminin in the
mammalian adult brain; it is critical for hippocampal neuronal survival and is expressed by
glial cells after CNS injury. The KDI peptide is derived from ?1 laminin as a neurotrophic
peptide.
In this thesis study, we analyzed the role of ?1 laminin and its KDI peptide in
different settings of CNS injury. An experimental cell-culture model mimicking a damaged
CNS environment showed that the KDI peptide has a stimulating effect on neuronal sur-
vival and neurite outgrowth. We analyzed neurons from human embryonic spinal cord, ret-
ina, and neocortex, leading to findings that both neuronal survival and neurite outgrowth
were stimulated by the soluble KDI peptide in all of these tissues.
A stereotaxic injection of kainic acid into rat hippocampus was done for test-
ing the possible protective effect of the KDI peptide. A preceding injection of the KDI
peptide protected both hippocampal and neocortical areas of excitotoxic brain damage
caused by kainic acid. Kainic acid alone caused serious tissue damage to the hippocampal
and neocortical injection sites.
The KDI peptide showed inhibition of glutamate excitotoxicity by inhibiting
kainate, AMPA, and NMDA subclasses of glutamate receptors in patch clamp recordings.
Neurons were cultured from human embryonic neocortex and from HEK 293 cells ex-
pressing recombinant glutamate subunits. These studies indicate that the KDI peptide of ?1
laminin enhances neuronal survival and protects against glutamate excitotoxicity at least
partially through inhibition of various glutamate receptors.
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Following middle cerebral artery occlusion leading to focal brain ischemia in
rats, various laminins were mapped both spatially and temporally. Laminin-1 was in-
creased in basement membranes and scar-forming extracellular matrix; ?1 laminin was in-
duced earlier than other laminins and expressed by reactive astrocytes. Similarly, the KDI
peptide of ?1 laminin was expressed by reactive astrocytes surrounding the ischemic re-
gion but detected along major neuronal pathways as well. The different patterns of laminin
expression suggest involvement of different laminins in different functions in the patho-
physiology of experimental brain ischemia. In general, these studies present novel data on
the expression of laminins in the healthy and damaged brain, demonstrate protective ef-
fects of the KDI tripeptide of ?1 laminin in cell cultures and in vivo in the brain, and give
clues as to the mechanisms of KDI peptide neuroprotection.
9INTRODUCTION
THE VULNERABLE CENTRAL NERVOUS SYSTEM
During the past two decades neuroscience has developed greatly. One of the major chal-
lenges has been regeneration of the central nervous system (CNS). In the peripheral nerv-
ous system (PNS) injured axons often regenerate, but in the CNS, injury is usually perma-
nent. This injury often leads to serious functional deficits and traumatizes the individual
both physically and mentally. Current therapies in human CNS injury are primarily based
on rehabilitation  (Tsai and Tator, 2005), although several molecular and cellular strategies
are being tested on animals (Thuret et al., 2006), and there is a desperate need for new
treatments.
Until the beginning of the 1980s, it was unclear whether the lack of regenera-
tion capacity in the CNS was from an intrinsic neuronal inability or lack of growth factors.
Experiments testing differences in growth environments between the PNS and CNS show
that peripheral nerves do not grow in a CNS glial environment (Aguayo et al., 1981), in
opposition to CNS neurites that grow through transplanted PNS grafts (David and Aguayo,
1981). These findings show that neurons of the CNS can succeed in regenerating, and the
influence of the environmental factors plays a central role. The major physical and molecu-
lar structures of inhibition in the spinal cord (SC) at cellular level seem to be the glial scar
and myelin. Several molecules have been shown to interact in these inhibitory systems and
are further specified later in the text. Focusing on inhibitory and stimulating factors of
nerve regeneration after injury has produced many promising cellular and molecular
strategies being tested in animal experiments on enhancing neurite outgrowth.
Injury in the CNS results from either trauma or disease. Disease can be of both
an acute and chronic nature whereas trauma is always acute. Depending on the nature of
damage to the CNS, the mechanisms activated on a cellular and molecular level differ.
Acute cerebral ischemia causes early excitotoxicity, inflammation, blood-brain-barrier
(BBB) disruption, and brain edema, leading to both programmed apoptosis and passive
neuronal necrosis (Dirnagl et al., 1999, Ayata and Ropper, 2002). Spinal cord injury (SCI)
can result from various types of injury: in the acute phase, via actual physical trauma, oxi-
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dative stress, excitotoxicity, edema, and hemorrhagic toxicity, all leading to functional
loss. Secondary processes such as apoptosis, demyelinization, and inflammation further
affect and cause deterioration in the SCI (Crowe et al., 1997, Jones et al., 2005). The most
common diseases that cause neuronal degeneration in their own specific manner are Alz-
heimer’s disease (AD), stroke, Parkinson's disease (PD), amyotrophic lateral sclerosis
(ALS), multiple sclerosis (MS), and various bacterial and viral infections. Toxic damage to
the CNS can be induced by drugs, alcohol, chemical compounds, or diseases such as acute
liver failure. A variety of animal models allow testing of  human CNS injuries and diseases
(Tatlisumak and Fisher, 2006). Interestingly, various major CNS diseases involve similar
injury and repair mechanisms.
Some spontaneous repair and collateral sprouting are evident after SC damage
even though restoration of functional loss is poor (Stichel and Muller, 1998). Similarly,
new neurons are created in the human CNS, although selectively and mainly in the olfac-
tory bulb, subventricular zone, and hippocampus (Falk and Frisen, 2005). Since these
adaptive changes in the CNS are insufficient, CNS damage often leads to permanent and
severe functional loss. All mechanisms and interventions that may enhance regeneration in
the brain and hence attenuate functional loss are therefore a target of intense research.
11
REVIEW OF THE LITERATURE
1. EXTRACELLULAR MATRIX AND THE BASEMENT MEMBRANE
The extracellular matrix (ECM), which fills the pericellular space, has been defined as a
composition of mainly different glycoproteins and proteoglycans. The basement membrane
(BM) is a thin structure considered a specialized ECM and mainly comprises type IV col-
lagens, laminins, perlecan, nidogens, and other molecules (Colognato and Yurchenco,
2000, Yurchenco et al., 2004). The BM separates different cells from their underlying tis-
sues, it provides mechanical stability, and it takes part in cellular functions such as migra-
tion, proliferation, and cell survival (Timpl and Brown, 1996). The many functional prop-
erties are often linked with molecular interaction of the BM (Yurchenco et al., 2004).
Many ECM molecules are thus considered to be BM-associated molecules but are not con-
stituents of the actual BM structure. The term “basement membrane” was used after its ap-
pearance in light microscopy, and with electron microscopy its structure can be further dis-
tinguished into layers known as the lamina rara externa (or lamina lucida), lamina densa,
lamina rara interna, and lamina fibroreticularis (Laurie et al., 1982, Leblond and Inoue,
1989). The term “basal lamina” can serve to describe the first three layers above, but ac-
cording to today's practice the term BM includes all four layers. Because the basal lamina
connects to the lamina fibroreticularis, containing collagen fibrils, it connects to the under-
lying tissue (Merker, 1994)(Figure 1).
The molecular composition of the ECM can be diverse and therefore provide
the BM with many functional abilities. Since the ECM molecules can bind and send sig-
nals to surrounding cells, they reflect the functions of the tissues they surround. The ECM
takes part in tissue maintenance and is also a dynamic medium for molecular signalling
(Yurchenco and Schittny, 1990).
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Figure 1. A simplified scheme of basement membrane (BM) structure. 1. Epithelium. 2.
Lamina rara externa (or lamina lucida). 3. Lamina densa. 4. Lamina rara interna. 5. Lamina
fibroreticularis. Three layers can be designated basal lamina (BL).
2. LAMININS
2.1. Nomenclature
Several classifications allow for classification of laminins and the composition of their
chains. The first laminin chains identified were called A, B1, and B2 chains, later re-
named as a, b, and g. A nomenclature was created around the Greek vocabulary to identify
the laminin isoforms composed of the a, b, and g chains (Burgeson et al., 1994). A hetero-
trimeric isoform of laminin is formed by one chain from each class. Arabic numbers are
combined with the Greek letters that describe the chain so that each isoform can be classi-
fied in the order of its discovery (Burgeson et al., 1994). For example, laminin-1 would be
described as a1b1g1 and laminin-2 as a2b1g1, often also with their chain assembly in pa-
renthesis (Table 1).
In 2005 came a new nomenclature, no longer using Greek letters for the com-
position of the different chains but three Arabic letters representing each chain (Aumailley
et al., 2005), and the first number representing the ? chain, the second the ? chain, and the
third number the ? chain. For example, laminin-1 would be called laminin-111, because its
chain composition is a1b1g1; laminin-2 is called laminin-211 (Aumailley et al., 2005),
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since it is the first laminin described with a variant form of the ? chain a2b1g1. According
to this system the list goes on. This thesis, however uses the nomenclature created earlier
(Burgeson et al., 1994), since the publications presented in this study have used both Greek
and Arabic letters to describe laminin chains.
2.2. Structure
Laminin-1 (a1b1g1) is a cross-shaped glycoprotein with three short arms and one long arm
(Engel et al., 1981). It is composed of three polypeptides that consist of several different
domains, a1 with nine domains (Sasaki et al., 1988), b1 with seven (Sasaki et al., 1987),
and g1 with six (Sasaki and Yamada, 1987). Laminin-1 was originally purified from the
Engelbreth-Holm-Swarm tumor (Timpl et al., 1979), and the structures of the human and
mouse laminin-1 (Pikkarainen et al., 1987, Sasaki et al., 1987, Sasaki and Yamada, 1987,
Pikkarainen et al., 1988, Nissinen et al., 1991) were found to be  compatible with the puri-
fied protein (Sasaki et al., 1988). The N-terminus of laminin-1 is composed of the three
short arms of the a, b, and g chains. The N-termini of these chains are closely related and
consist of domains III toVI. The long arm of laminin-1, consisting of domains I and II, has
a rod-like structure in which the C-terminal of the three chains are combined. A globular
G-domain extends to the a1 chain in the C-terminal. Almost in the center of the laminin
cross in domain II, and in domain I near the globular C-terminal part, the three polypeptide
chains are linked by disulfide bonds (Engel et al., 1981, Beck et al., 1993) (Figure 2).
The three monomeric polypeptide chains forming laminin-1 vary in molecular
weight depending on tissue and species as well as on their degree of glycosylation (Engel
et al., 1981, Beck et al., 1990, Beck et al., 1993, Burgeson et al., 1994). Laminin-1 is a
highly glycosylated protein, meaning that 25 to 30% of its molecular weight is formed by
carbohydrate (Knibbs et al., 1989). Laminin-1 also contains many N-glycosylation sites—
74 potential sites (Beck et al., 1990)— reported to play a functional role in multiple cellular
properties such as neurite outgrowth, tumor cell adhesion, cell migration, and molecular
interactions (Dennis et al., 1984, Dean et al., 1990, Chammas et al., 1991).
The short arms in the N-terminal of laminin-1 contain cysteine-rich residues.
These residues are closely related to the epidermal growth factor (EGF) (Engel, 1989). In
Ron Liebkind
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the b1 and g1 polypeptide chains two cysteine-rich EGF-like repeats occur in domains III
and V (Sasaki et al., 1987, Sasaki and Yamada, 1987). Similarly, in the a1 chain, three
cystein-rich chains occur in domains IIIa, IIIb, and V (Sasaki et al., 1988) (Figure 2).
The long arms of the polypeptide chains of laminin-1 form double- and triple-
stranded coiled-coil structures and require a short sequence at the C-terminal of each chain
(Utani et al., 1994, Utani et al., 1995). There is a low sequence homology of the polypep-
tide long arms, but they all include repeating sequences of seven residues that allow them
to coil around each other (Beck et al., 1990, Beck et al., 1993). The b and g chains first
form a dimeric structure and then follow a trimeric formation with the a chain (Peters et
al., 1985, Utani et al., 1994, Utani et al., 1995, Nomizu et al., 1996).
Table 1. Laminin trimers, nomenclature, and chains
Former name chains new name
Laminin-1 ?????1 Laminin-111
Laminin-2 ?????1 Laminin-211
Laminin-3 ?????1 Laminin-121
Laminin-4 ?????1 Laminin-221
Laminin-5a ?3A???2 Laminin-332
Laminin-5b ?3B???2 Laminin-3B32
Laminin-6 ?????1 Laminin-311
Laminin-7 ?????1 Laminin-321
Laminin-8 ?????1 Laminin-411
Laminin-9 ?????1 Laminin-421
Laminin-10 ?????1 Laminin-511
Laminin-11 ?????1 Laminin-521
Laminin-12 ?????3 Laminin-213
Laminin-14 ?????3 Laminin-423
Laminin-15 ?????3 Laminin-523
15
Figure 2. Laminin-1 structure, ?????1 trimer, including domain structure indicated with
Roman numerals (I-IV, ?) according to the earlier nomenclature (Burgeson et al., 1994)
and within parenthesis newly proposed (laminin-111) nomenclature (coiled-coil, LN, LEa,
LEb, L4a, L4b, LEc, L4, LF, L?)(Aumailley et al., 2005). A finger domain of ?1 laminin
contains five globular domains (G or (LG)). “Hinge” indicates an inter-domain bridge be-
tween marked globular domains.
Ron Liebkind
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Table 2. Laminin receptors
Integrins: ???1, ???1, ???1, ???1, ???1, ???4
67/68-kDa laminin receptor
?-dystroglycan
2.3. Role in CNS development
Laminin-1 is known for its central part in the architecture of the BMs in almost all mam-
malian tissues. Its fundamental role appears during development in both embryonic and
extraembryonic BMs starting from embryonic implantation (Leivo et al., 1980, Dziadek
and Timpl, 1985, Miner et al., 2004) and also taking part in organ development (Miner and
Yurchenco, 2004). The ?1 chain of laminin-1 is required for endodermal differentiation
and formation of the BM (Halfter et al., 2002).
In Drosophila, laminin is essential for CNS function and proper development
of the visual system (Garcia-Alonso et al., 1996), and in Xenopus it also seems to play a
central role during CNS development (Lallier et al., 1996). In Drosophilia and C. elegans,
two laminins are relevant for viability and are essential even in intervertebrate develop-
mental functions (Huang et al., 2003).
Mutations in mammalian laminin genes representing the heterotrimers
laminin-1 and -10 are fatal to the embryo and lead to defects in gastrulation, in neural tube
closure, and in placentation (Miner et al., 1998, Smyth et al., 1999, Miner et al., 2004).
Other reports on mutations in laminin genes show a more organ-specific defect less fun-
damental to early embryonal development, such as in the kidney (Noakes et al., 1995,
Miner and Li, 2000), lungs (Nguyen et al., 2002), placenta (Miner et al., 1998), retina
(Libby et al., 1999), PNS (Chen and Strickland, 2003), pancreas (Miner et al., 2004), and
in skin/epithelial disruption (McLean et al., 2003) and CNS myelinization (Chun et al.,
2003). Laminin receptor mutations also show the importance of molecular interaction in
the developing brain: in conditional knockouts affecting dystroglycan and in integrin ?1,
resulting in disruption of the pial membrane (glia limitans) (Graus-Porta et al., 2001,
Moore et al., 2002). Mutation of the nidogen binding site of ?1 laminin leads to a disrup-
tion of their interaction and also leads to discontinuites in the pial membrane together with
neuronal migration errors (Moore et al., 2002). For major laminin receptors see Table 2.
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2.4.CNS distribution
In the healthy CNS, laminin depositions appear mainly in the vascular- and pial BMs and
the choroid plexus (Martin and Timpl, 1987, Miner and Yurchenco, 2004). In hippocampal
cell layers, laminin-1 can be detected in neurons of both the developing and adult rat brain
(Hagg et al., 1989). Laminin chain ?5, ?1, and ?1 expression in the hippocampal neuronal
layers (CA1, CA5, and dentate gyrus) seem to be the highest (Indyk et al., 2003). Addi-
tionally, neuronal expression of laminin-1 occurs in the neocortex of the adult rat, and its
?1 chain actively participates in modulating neuronal activity (Hager et al., 1998).
In the adult mammalian CNS, ?2 laminin is associated with neuronal tracts of
the limbic system, and the ?1 chain appears throughout the brain in neuronal cell bodies
(Hagg et al., 1997). The ?3 laminin expression has been characterized not only in BM
structures but also in different structures of the brain (Koch et al., 1999).
Neurons expressing genes of the laminin subtypes ?1, ?5, ?1, and ?1 were
studied by use of a ?-geo marker in gene trapping methodology (Yin et al., 2003). Expres-
sion of ?1 and ?1 laminin immunoreactivity was evident but no ? chain in adult mouse
neurons in the cerebral cortex, hippocampus, and retina. A co-trapping method was also
used to show that ?1 laminin and ?1 laminin can form a protein complex intracellularly,
and since no ? chains were expressed here, the secretion of a laminin dimer was possible
(Yin et al., 2003). In the same experimental assembly, ?5 chains occurred in the choroid
plexus and vascular basement membrane. Lack of the ?1 subunit, but expression of ?1 and
?1 laminin, are possible in both mouse brain and astrocyte cultures from rat cortex and ol-
factory bulb, where a dimeric laminin-1 was a possibility (Liesi and Risteli, 1989). Many
studies show laminin subunit expression in the CNS in astrocytes and neurons.
Many of these studies show laminin subunit expression, but whether all sub-
units can be independently secreted to the extracellular space still remains unclear since
some propose that the ?1 chain drives the secretion of ?1 and ?1 laminins (Yurchenco et
al., 1997, Miner and Yurchenco, 2004).
Rat brain astrocytes in primary culture express laminin-1; the younger the
source, the longer the expression. The same astrocytes, positively double immunostained
by glial fibrillary acidic protein (GFAP) and laminin-1, were cultured from embryonic,
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newly born, and 5-day-old rat brain (Liesi et al., 1983). A neurotoxic injury to the rat brain
induces laminin-1 in reactive astrocytes (Liesi et al., 1984). In both normal and pathologi-
cal CNS, laminins are expressed in neuroectodermal cells (Bernstein et al., 1985). In AD,
laminin-1, ?1, and ?1 laminin occur in reactive astrocytes and the ?1 chain could be local-
ized to the senile plaques typical for AD pathology (Palu and Liesi, 2002). After SCI in
adult rats, ?1 and ?1 laminin can also be detected in reactive astrocytes (Liesi and Kaup-
pila, 2002, Wiksten et al., 2004).
2.5. Migration and axonal growth
Through its neurotropic properties— participating in directing neurite growth— laminin
plays an important role in the developmental process which involves migration and forma-
tion of neuronal pathways. In vitro, laminin-1 promotes the axonal growth activity of cen-
tral neurons (Manthorpe et al., 1983), and in the developing rat brain, in vivo expression of
laminin-1 coincides with neuronal migration (Liesi, 1985). Laminin-1 is expressed
throughout the embryonic and early developing CNS, often correlating with neuronal
pathways and migration (Cohen et al., 1987, Liesi and Silver, 1988, Morissette and Car-
bonetto, 1995). Both neurons and glial cells synthesize ?, ?, and ? chains of laminins in the
developing mammalian CNS (Libby et al., 2000, Liesi et al., 2001, Wiksten et al., 2003). A
different expression pattern of the laminin isoforms in human embryonic SC and brain has
also been reported (Liesi et al., 2001). Laminin isoforms ?1, ?1, ?3, and ?1 are associated
with axonal guidance and are also localized in the floor plate of the developing embryonal
human SC (Wiksten et al., 2003).
Retinal ganglion cells need laminin-1 during development for the neurite out-
growth and neuronal guidance in which they themselves actively participate. Interestingly,
this response is lost during maturation (Cohen et al., 1986, Cohen et al., 1987). In the ret-
ina, ?2 laminin expression in particular has been connected with synapse development and
outer layer photoreceptor morphogenesis (Libby et al., 1996, Libby et al., 1997); other
laminins such as ?2, ?3, ?4, ?5, ?3, ?2, and ?3 can occur outside the retinal BM (Libby et
al., 2000). Characterization of these subunits led to characterizing two new laminin hetero-
trimers (Libby et al., 2000). Laminin ?2 is expressed when retinal pathways start to de-
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velop within the brain (Morissette and Carbonetto, 1995). Laminin ?2 has been identified
in the CNS through dysfunctional states: A mutation in the ?2 laminin has been associated
with dysmyelinization, lack of development, and muscular dystrophy (Sunada et al., 1995,
van der Knaap et al., 1997). The connection to demyelinization is through the oligodendro-
cyte laminin receptors (Colognato et al., 2007).
Laminin-1 expression is connected with neuronal survival in the hippocampus,
and degradation of laminin makes them more susceptible to dying (Chen and Strickland,
1997); the ?1 chain seems to be of specific importance in this process (Chen et al., 2003).
An axon regeneration model of the CNS, in lesioned hippocampal slices, shows that ?1
laminin plays a central role in neuronal regeneration, and that hippocampal neurons syn-
thesize ?1 laminin (Grimpe et al., 2002). The hypothesis of ?1 laminin involvement as an
axon growth-promoting laminin isoform was tested in culture studies using synthetically
derived peptides. A decapeptide (RDIAEIIKDI) of ?1 laminin, from the C-terminal part,
promoted neurite growth of both central and peripheral neurons (Liesi et al., 1989). The
same decapeptide of ?1 laminin also occurs in the hippocampus (Matsuzawa et al., 1996).
Furthermore, a tripeptide (KDI), derived from the same decapeptide, induces potassium
currents in central neurons and mediates the neuronal outgrowth-stimulating properties of
?1 laminin (Liesi et al., 2001). Matrigel cultures show how neurites from spinal cord ex-
plants tend to grow towards and into matrigel if it has added KDI (Wiksten et al., 2003).
In the cerebellum, between the meningeal layer and the Purkinje cell layer lies
an external granular layer (Goldowitz and Hamre, 1998, Wang and Zoghbi, 2001) in which
granular precursor cells express laminin receptors of integrin ? type, and the proliferating
cells are in close association with laminin isoforms embedded within the BM (Blaess et al.,
2004). Within this granular layer, laminin enhances the effects of sonic hedgehog (Ssh)
and induces proliferation (Pons et al., 2001, Lewis et al., 2004).
2.6 Fragments, peptides, and their functions
Using enzymes to split laminin-1 into fragments could localize this molecule’s different
functions (Engel et al., 1981, Ott et al., 1982, Bruch et al., 1989). With proteolytic en-
zymes such as pepsin, elastase, cathepsin-G, and trypsin, functional studies could reveal
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fragments active in cell attachment (Timpl et al., 1983), mitosis (Panayotou et al., 1989),
and nidogen binding (Paulsson et al., 1987). Use of elastase in a similar manner allowed
neuronal outgrowth capacity to be localized to the E8 fragment of laminin-1 (Edgar et al.,
1984). In this fragment, the peptides RDIAEIIKDI and KDI may also be located. The
fragments defined are in Figure 3.
Amino-acid sequencing of laminin-1 fragments has enabled further investiga-
tion and definition of the laminin-1 peptides and their biological functions. Eleven neuron-
ally active laminin-1-derived peptides and their functional activities are presented in Table
3.
Figure 3. Proteolytic fragments of laminin-1. Enzymes used to cleave laminin-1 into ex-
perimental fragment C by cathepsin-G , E by elastase, P by pepsin, T by trypsin. The 25K
fragment was generated by treating mouse tumor laminin-1 with clostripatin-containing
collagenase and purifying its trypsin digests (Timpl et al., 1979). The P1' fragment is par-
tially cleaved, but disulphide bridges hold it together (Aumailley et al., 2005). The globu-
lar domains of ?1 laminin are presented here as the spheres 1 to 5.
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Table 3. Laminin-1 derived peptides and their neuronal functions.
Loca-
tion
Function Peptide Reference
?1 G Neurite outgrowth KATPMLKMRTSFHGCIK (Skubitz et al., 1991)
?1 G Neurite outgrowth KEGYKVRDLNITLEFRTTSK (Skubitz et al., 1991)
?1 G Neurite outgrowth KNLEISRSTFDLLRNSYGRK (Skubitz et al., 1991)
?1 G Neurite outgrowth DGKWHTVKTEYIKRKAF (Skubitz et al., 1991)
?4 G Neurite outgrowth LAIKNDNLVYVY (Ichikawa et al.,
2005)
?4 G Neurite outgrowth DVISLYNFKHIY (Ichikawa et al.,
2005)
?4 G Neurite outgrowth VIRDSNVVOLDV (Ichikawa et al.,
2005)
?4 G Neurite outgrowth, peptide
in cyclic form
CTLFLAHGRLVFX (Ichikawa et al.,
2005)
?2 I Inhibition of neurite out-
growth
LRE (Porter et al., 1995)
Neuronal cell attachment (Hunter et al., 1989)
Promotion of motor axon
growth
(Brandenberger et al.,
1996)
?1 I Neurite outgrowth, neuro-
trophic and neurotoxic ef-
fect, activation of potas-
sium currents
RDIAEIIKDI (Liesi et al., 1989,
Liesi et al., 2001)
Neuronal migration and
nuclear translocation
(Liesi et al., 1995)
Axonal differentation and
guidance
(Matsuzawa et al.,
1996, Matsuzawa et
al., 1998)
?1 I Guidance of neurite out-
growth
KDI (Wiksten et al., 2003)
Regeneration of SCI (Wiksten et al., 2004)
Neurite outgrowth and ac-
tivation of potassium cur-
rents
(Liesi et al., 2001)
Protection against 6-OHDA (Väänänen et al.,
2006)
Studies in Table 3 show results using primary neurons in their experimental setting. Amino acids:
A, alanine; R, arginine; N, aspargine; D, aspartic acid; C, cysteine; Q, glutamine; E, glutamic acid;
G, glycine; H, histidine; I, isoleucine; L, leucine; K, lysine; M, methionine; F, phenylalanine; P,
proline; S, serine; T, threonine; W, tryptophan; Y, tyrosine; V, valine.
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3. MECHANISMS OF INJURY
3.1 Excitotoxicity
In the CNS the major excitatory neurotransmitter is glutamate. Its release from neuronal
synapses leads to neuronal glutamate receptor stimulation and excitatory synaptic trans-
mission. Glutamate and its receptors are central communicative constituents for neurons;
they support neuronal network activity and play an important role in maintaining both
normal and pathological conditions in the CNS.
Excitotoxicity contributes in both acute and chronic CNS diseases to neuronal
degeneration. Often a lack of oxygen or of glucose leads to depolarization of neurons
which leads in turn to the release of glutamate into the extracellular space. Uptake of glu-
tamate by astroglial cells is hampered during ischemia and hypoxia, resulting in even
higher glutamate concentrations in the postsynaptic cleft. Excessive glutamate release can
lead to a disruption of Ca2+ homeostasis (Choi, 1995). It is suggested that because gluta-
mate toxicity is primarily dependent on Ca2+ influx, ionotrophic glutamate receptors may
play a key role (Choi, 1987, Choi et al., 1987). The ionotrophic glutamate receptors have
traditionally been classified into three subtypes, N-methyl-D-aspartate (NMDA), ?-3-
amino-hydroxy-5-methyl-4-isoxalolepropionate (AMPA), and kainate (KA) receptors.
When they are activated, their ion channels open for influx especially of Ca2+ and Na+ ions
into neurons. Activation of metabotrophic receptors leads to release of intracytoplasmic
Ca2+ stores, further increasing the cytoplasmic calcium overload. The rise in intracellular
calcium stimulates intracellular neurotoxic pathways and enzymes, neuronal mitochondri-
cal respiration is impaired, and cessation or near cessation of adenosine triphosphate
(ATP) production occurs. Furthermore, production of reactive oxygen radicals and activa-
tion of apoptotic signals extend CNS tissue damage. Prior to the Ca2+-dependent excitotox-
icity, the entry of Na+ and Cl- ions into neurons leads to acute cellular swelling called cyto-
toxic edema (Dirnagl et al., 1999, Arundine and Tymianski, 2003, Arundine and Tymian-
ski, 2004).
Glutamate receptors, which can be found throughout the brain, participate in
the pathophysiology of many brain diseases and CNS trauma. Mediating excitotoxicity,
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they may take part in ischemic brain damage (Hossmann, 1994), epilepsy (Swann et al.,
2000), and brain injury caused by trauma (Siesjo et al., 1995). Neurodegenerative diseases
such as AD (Smith-Swintosky and Mattson, 1994), PD (Beal, 1998), Huntington’s disease
(Ross et al., 1997), and ALS (Eisen and Weber, 2001) involve excessive glutamate recep-
tor stimulation and thereby neuronal cell death.
3.2 Trauma
Traumatic CNS injury has several forms including mechanical, chemical, thermal, and
electrical. Among these, mechanical trauma is overwhelmingly the most common and
most disabling. A traumatic blow to the brain or SC results in both acute and secondary
tissue damage to the CNS. In the acute reaction, direct cell death occurs at the damage site.
Neurons, astrocytes, oligodendrocytes, and endothelial cells suffer from acute cell death,
and lack of both oxygen and glucose further damages the tissue. Hemorrhage, vascular
damage, inflammation, and edema follow and contribute to the acute phase of the injury
(Hagg and Oudega, 2006).
Head trauma can be both focal and diffuse, depending on the mechanism of
impact (Gennarelli et al., 1982) (Medana and Esiri, 2003). Since research on the molecular
mechanisms of CNS trauma is more clearly defined regarding spinal cord injury, and most
of the pathophysiological mechanisms in brain and SC trauma are similar, the following
insights into secondary traumatic CNS tissue damage will be studied with focus on the SC.
Acute cell death spreads through secondary mechanisms of injury in the white matter of
the SC where extracellular glutamate also participates, through excitotoxicity to continu-
ous neural damage (Park et al., 2004).The secondary processes continue to hamper the
function of the already damaged SC through apoptosis of oligodendrocytes and loss of
myelin (Crowe et al., 1997), and demyelinization can continue for months and possibly for
years (Guest et al., 2005). During the first 3 to 7 days, many inflammatory cells such as
monocytes, macrophages, microglia, and T-lymphocytes can be identified in the SCI area
(Popovich et al., 1997). Many mechanisms contribute to necrotic cell damage: nitric oxide
(NO) production, Ca2+ homeostasis disruption, membrane breakdown, and oxidative stress
(Casha et al., 2001). During the secondary phase, a scar forms in the SC, also known as the
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glial scar, its molecular constituents actively repelling axonal growth (Rhodes and Fawcett,
2004). The glial scar is formed around the lesion site and contains reactive astrocytes
(McKeon et al., 1991). Moreover, meningeal fibroblasts and macrophages invade the le-
sion site, creating a more fibrous scar, adding to the mechanical obstacle against neurons’
growing and re-forming networks (Stichel and Muller, 1998, Preston et al., 2001).
3.3 Ischemia
3.3.1 Focal brain ischemia
In treating patients with functional impairments caused by CNS damage, the vulnerability
of the human CNS is always a challenge. One of the most common causes of CNS damage
is brain ischemia caused by a blood perfusion deficit. Since the neurons are unable to store
valuable resources of energy such as glucose or oxygen, their survival is dependent on a
continuous supply through the blood circulation.
Focal brain ischemia is caused by lack or critical attenuation of blood flow to
one region of the brain. Depending on the site of vascular occlusion, various parts of the
brain can be affected and clinically recognized based on signs, symptoms, and imaging
studies. Ischemic brain damage has a complex pathophysiology. Decreased blood flow
leads to a lack of substrates for the cells that are dependent on both glucose and oxygen,
causing depolarization of neurons and astroglia. Excessive amounts of glutamate are re-
leased to the extracellular space, and through receptor activation, intracellular calcium
rises (see part 3.1). Due to the vascular occlusion and reduction in blood flow, disruption
of the BBB follows, leading to brain edema and escalation of inflammatory processes. The
cause of BBB breakdown is believed to be connected with proteases such as the matrix
metalloproteases destroying the basal lamina, inflammatory molecules, and free radicals.
The free radicals arise mainly due to a lack of substrate (glucose, oxygen), leading to an-
aerobic glycolysis and acidosis. They generate an increase in intracellular Ca2+, Na+, and
Cl- ions, thus leading to apoptosis and necrosis. Postischemic inflammation has many
components, microglia and leukocytes being important ones (Stoll et al., 1998). Ischemia-
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induced upregulation of adhesion molecules leads to recruitment of circulating leukocytes
to the surface of endothelial cells (Lindsberg et al., 1996) and through pro-inflammatory
cytokines infarct volume further increase (Relton et al., 1996).
3.3.2 Ischemic brain edema
On the cellular level, two types of edema after ischemia are usually recognized. Cytotoxic
edema, described as cellular swelling, is mainly caused by sodium influx into cytoplasm,
followed by water. Na+ and Ca2+ ion influx is partly the result of neurotransmitter stimula-
tion of ligand-gated receptors. The Ca2+ overload and the cellular swelling is thought to be
cytotoxic for the injured cells (Choi, 1992, Neumann-Haefelin et al., 2000). Vasogenic
edema, also described as the extracellular component of brain swelling, is caused mainly
by a disrupted BBB (Ayata and Ropper, 2002). Contributing to the endothelial damage and
vascular permeability, leading to a shift of water to the extracellular compartments, are in-
flammatory processes and free radicals. Further damaging the BBB and increasing its per-
meability are matrix metalloproteases that actively break down the matrix proteins in the
basal lamina (Mun-Bryce and Rosenberg, 1998).
3.4 Kainic acid-induced neurotoxicity
Kainic acid (KA) is a neurotoxic glutamate agonist (Olney et al., 1974). A well-described
model for studying neurodegeneration is the injection of kainic acid into the hippocampus
(Ben-Ari et al., 1979). Kainic acid binds non-NMDA-type glutamate receptors (AMPA
and kainate receptors) and takes part in excitotoxic cell death (Chen et al., 1995). Activa-
tion of kainate receptors raises intracellular calcium, the production of reactive oxygen
species, and mitochondrial dysfunction, all leading to apoptotic cell death in neurons
(Cheng and Sun, 1994, Milatovic et al., 2002). In the rat hippocampus, after KA injection,
proliferation of astrocytes and microglia is evident (Wang et al., 2005). KA has been use-
ful for studying neurological conditions such as epileptic seizures (Ben-Ari, 1985), Hunt-
ington’s disease (Coyle et al., 1983), AD (Coyle et al., 1983), and trauma (Wang et al.,
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2005). It has been applied both in vivo and in vitro to test pharmacological and neuropro-
tective compounds against excitotoxic events in the CNS. Intrahippocampal, intracere-
broventricular, and systemic administration of KA has been a tool in various settings for
study of neurodegeneration (Ben-Ari, 1985). Neurodegenerative changes, especially in the
hippocampus, are of value in studying areas such as the CA1 and CA3, where pyramidal
neurons as well as interneurons in the hilus of the dentate gyrus (DG) are particularly vul-
nerable to KA (Ben-Ari, 1985, Grooms et al., 2000). Interestingly, pyramidal cells in the
hippocampal CA2 and glomerular cells of the DG seem to be more tolerant to excitotoxic-
ity (Grooms et al., 2000, Oprica et al., 2003). The molecular basis for this difference may
be the diverse expression of kainate and AMPA receptors, which thereby influence the
sensitivity of Ca2+ permeability and the selective vulnerability of the specific region
(Malva et al., 1998, Grooms et al., 2000, Weiss and Sensi, 2000). Excitotoxic cell death
caused by KA may be inhibited by the AMPA receptor antagonist CNQX (6-cyano-7-
nitroquinoxalone-2, 3-dione), but not by use of an NMDA or a membrane calcium antago-
nist; this fact shows the central position of the AMPA receptor in this model of injury (Li
et al., 2003).
3.5 Inflammation
Immediately following lesioning in the CNS, inflammatory cells migrate to the site of in-
jury. Macrophages, T-cells, and neutrophils migrate from the periphery towards the lesion
and are joined by activated astrocytes and microglia (Popovich et al., 1997, Bethea and
Dietrich, 2002). Maximal infiltration of the inflammatory cells can be seen 3 to 7 days
post-injury (Popovich et al., 1997). Following injury, the invading leukocytes take part in
activating the inflammatory response in macrophages. Macrophages can be actively local-
ized at the injury site, and their number starts to decline 7 days post-injury; at the primary
SC lesion, microglia also are present for up to 2 to 4 weeks (Popovich et al., 1997). Neu-
trophil activation to the injury is rapid and starts to decline 48 h after injury (Taoka et al.,
1997). Neutrophils and macrophages also contribute to the secondary damage by taking
part in tissue destruction (Taoka et al., 1997, Gris et al., 2004). Primarily produced by
macrophages and microglia, pro-inflammatory chemokines and cytokines (tumor necrosis
factor (TNF); interleukin-1, -6, -10, and interferon) further provoke the damage (Bartholdi
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and Schwab, 1997, Klusman and Schwab, 1997). A vicious circle continues through induc-
tion of reactive oxygen, nitric oxide, and additional chemokines/cytokines (Bredt and Sny-
der, 1994, Xu et al., 2001). Over-expression of these toxic molecules further damages the
SC, contributes to scar formation, and hampers axonal growth (Jones et al., 2002).
3.6 Apoptosis
Programmed cell death is a natural process in the developing CNS (Blomgren et al., 2007).
Premature cell death, also known as pathological apoptosis, is associated with many neu-
rodegenerative disorders such as AD, PD, ALS, stroke, and brain and spinal cord trauma
(Heidenreich, 2003, Ekshyyan and Aw, 2004). When damage occurs in the CNS, some
cells die from direct necrosis, and others are programmed towards apoptosis. In many
cases the necrotic part of the lesion can be larger than the part affected by pathological
apoptosis. Necrosis is the dominant cell death mechanism within the ischemic lesion’s
core, whereas the role of apoptotic cell death is clearly greater within the penumbral region
(Li et al., 1998). The temporal profile also differs, with necrosis more instant, but apop-
tosis continuing for days, even for weeks, and also affecting projecting pathways (Schwab
and Bartholdi, 1996). Post-injury, apoptosis is activated by various stimuli and appears
over the same time-spectrum as do the inflammatory processes. Among the toxins pro-
duced by inflammation are oxygen free radicals, mediating apoptosis by mitochondrial and
DNA damage (Mabuchi et al., 2000). Apoptotic signalling can be caspase-dependent or
independent. Caspase-dependent apoptosis is mostly stimulated through “death receptors”
such as tumor necrosis factor receptors (TNFR) and Fas/CD95. These receptors are up-
regulated after SCI and traumatic brain injury (Casha et al., 2001, Keane et al., 2001), and
FAS deficiency reduces post-traumatic apoptosis (Casha et al., 2005). This pathway to-
wards apoptosis is also stimulated through mitochondrial damage and further activates
caspase-3 (Springer et al., 1999). Apoptosis-inducing factor (AIF) is a caspase-
independent inducer of cell death released from the mitochondrial intermembrane in re-
sponse to death stimuli (Joza et al., 2001). AIF causes chromatine condensation and DNA
fragmentation in the cell nucleus through large DNA strands (Lorenzo et al., 1999, Susin et
al., 1999). NMDA neurotoxicity, neurodegenerative disorders, and stroke itself activate a
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nuclear enzyme called poly(ADP-ribose) polymerase-1 (PARP-1) (Zhang et al., 1994, Eli-
asson et al., 1997, Endres et al., 1997) which mediates AIF signalling (Yu et al., 2002).
Antiapoptotic treatment is a intriguing target for neuroprotective research,
with some promising molecules proposed as having therapeutic properties in ischemic
brain damage. After cerebral ischemia, erythropoietin, which reduces ischemic neuronal
damage and neuronal dysfunction in rodent models of stroke (Sadamoto et al., 1998), pre-
vents neuronal apoptosis (Siren et al., 2001). Another interesting intervention with poten-
tial clinical implications is the inhibition or inactivation of PARP-1 which leads to preven-
tion of apoptotic cell death (Graziani and Szabo, 2005).
4. REGENERATION
In contrast to the PNS, where axonal regeneration is possible and can lead to functional re-
covery, axonal regeneration in the CNS is minimal, and functional loss is permanent. In
the PNS, following axiotomy, Wallerian degeneration— describing degeneration of the dis-
tal part of the damaged axon— takes place. Thereafter, Schwann cells catabolize myelin,
and macrophages are recruited to the injury site, participating in the removal of myelin-
and axonal debris. The remaining Schwann cells form guidance channels together with
chemoattractive factors with which the degenerated axons can start a regenerative process
through development of growth cones. Neuronal transformation into a regenerative mode
involves many molecular steps such as gene activation, upregulation of cytoskeletal pro-
teins, and outgrowth-stimulating factors (Johnson, 1993, Fu and Gordon, 1997).
CNS neurons do attempt to regenerate their damaged axons but usually end by
degenerating; this failure to regenerate is now well-accepted as crucially influenced by in-
hibitory factors in their environment (Stichel and Muller, 1998).
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4.1 Hampering factors
4.1.1 Glial scar
Axonal regeneration (sprouting) and networking may be hampered by scar tissue which
forms a mechanical barrier. After CNS injury, the scar consists of two areas, the lesion
core and the surrounding zone (Reier and Houle, 1988). The core of the lesion, often con-
sidered as permitting no regeneration, is populated by vascular endothelial cells, meningeal
fibroblasts, and oligodendrocyte precursors (OPCs). Surrounding the lesion are reactive
astrocytes, microglia, and OPCs (Fawcett and Asher, 1999). Post-traumatically, after a few
days, astrocytes become hypertrophic and up-regulate GFAP (Latov et al., 1979,
Mathewson and Berry, 1985) and later in the formation of the glial scar proliferate towards
the core of the lesion (Fawcett and Asher, 1999). Today, many inhibitory molecules pro-
duced by astrocytes are identified, and different experimental settings have shown their ef-
fects in hampering CNS regeneration (McGraw et al., 2001, Busch and Silver, 2007). Such
molecules as Semaphorin 3 (Pasterkamp et al., 2001), ephrin-B2 (Bundesen et al., 2003),
tenascin (Brodkey et al., 1995), and chondroitin sulphate proteoglycans (CSPGs) (Jones et
al., 2003) are among the molecules upregulated after injury. The core proteins of the
CSPGs are versican, neurocan, brevican, phosphacan, biglycan, aggrecan, and NG2
(Fawcett and Asher, 1999). These CSPGs are considered an important molecular group for
inhibition in the glial scar; axons growing from transplanted dorsal root ganglion (DRG)
stop at the site where CSPGs are expressed (Davies et al., 1999). The CSPGs localize
around several different CNS injury models, appear a few days after injury, and continue
to be expressed for weeks (Levine, 1994, Geisert et al., 1996). Not surprisingly, CSPGs are
in vitro a poor substrate for neurons to grow neurites (Snow et al., 1990). After brain or
spinal cord injury, regeneration of corticospinal or nigrostriatal tract axons can be pro-
moted by digesting CSPGs with chondroitinase ABC (Moon et al., 2001, Bradbury et al.,
2002). Interestingly, the sulphated glucosaminoglycan (GAG) chain of the CSPGs can
bind to growth-promoting molecules such as laminin and thereby inhibit further regenera-
tion (Smith-Thomas et al., 1995). Removal of the GAG chains from laminin allows promo-
tion of neurite outgrowth (McKeon et al., 1995).
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4.1.2 Myelin inhibition
The inhibitory effect of oligodendrocytes, white matter, and myelin is due to their mole-
cules that actively repel growing neurites (Schwab and Caroni, 1988). The myelin inhibi-
tory molecules are considered the second major source of inhibitory molecules in CNS re-
generation. When an injury occurs, myelin is disrupted locally and directly, since myelin-
based inhibitory molecules are expressed by normal oligodendrocytes in the CNS. To iden-
tify an inhibitory myelin molecule, in rat SC, antibody IN-1 was isolated, and showed
promise in regeneration in injured nerve fibers (Schnell and Schwab, 1990). IN-1 was later
designated Nogo, with now at least three isoforms of Nogo known (Nogo-A, -B, -C),
among which Nogo-A is the largest and is highly expressed in oligodendrocytes (Huber et
al., 2002). Nogo-A has two main active parts, one specific for Nogo-A (Oertle et al., 2003)
and another 66-amino-acid loop called Nogo-66 (Fournier et al., 2001) which is common
to all Nogo proteins. Both these two inhibitory domains are exposed to the ECM (Oertle et
al., 2003). The Nogo-66 domain inhibits neurite outgrowth through a receptor called NgR
(Fournier et al., 2001). Other myelin-associated molecules that can inhibit axon growth,
the myelin-associated glycoprotein and oligodendrocyte-myelin glycoprotein, also act
through the NgR receptor (Domeniconi et al., 2002, Liu et al., 2002). Myelin-associated
glycoprotein is a transmembrane glycoprotein with immunoglobulin-like domains first
identified in CNS myelin (McKerracher et al., 1994) and is also present in PNS Schwann
cells (Schachner and Bartsch, 2000). In embryonic mouse spinal cord, myelin-associated
glycoprotein has also shown neurite outgrowth-promotive effects (Turnley and Bartlett,
1998). Oligodendrocyte-myelin glycoprotein is a membrane myelin protein expressed by
oligodendrocytes in the CNS (Mikol et al., 1990).
4.2 Inducing factors
4.2.1 Neurotrophins
Neurotrophins are molecules often linked to neuronal survival, differentation, and devel-
opment. They consist of neuronal growth factor (NGF), brain-derived growth factor
31
(BDNF), neurotrophin-3 (NT-3), neurothrophin-4/5 (NT-4/5), neurotrophin-6 (NT-6), and
neurotrophin-7 (NT-7) (Lessmann et al., 2003). NGF, BDNF, NT-3, and NT4/5 have been
characterized (Lu et al., 2005) in the mammalian brain as well as their receptors, the Trk
family of receptor tyrosine kinases (TrkA, TrkB, TrkC) and the p75 neurotrophin receptor
(p75NTR) (Dechant and Barde, 2002, Huang and Reichardt, 2003). Astrocytes in the CNS
produce NGF, NT-3, and NT-4/5 (Yamakuni et al., 1987, Condorelli et al., 1995). After
spinal cord injury in rats, the reactive astrocytes upregulate NGF and BDNF (Goto and Fu-
rukawa, 1995). These are important for axonal branching (McAllister et al., 1995, Gallo
and Letourneau, 1998) and for establishing proper functional connections between neurons
(McAllister et al., 1999). In the hippocampus, BDNF infusions enhance neurogenesis and
formation of new granule cells (Scharfman et al., 2005).
4.2.2 Other growth factors
Fibroblast growth factor-2 (FGF-2) is actively expressed by astrocytes (Sensenbrenner,
1993) and can be localized in the hippocampus, cerebral cortex, and spinal cord (Riva and
Mocchetti, 1991). FGF enhances neurite growth and reduces gliosis in spinal cord grafts
(Giacobini et al., 1991). Mixing FGF into a fibrin graft and placing it into a rat SC lesion
model leads to regeneration of the corticospinal tract with improved levels of function
(Cheng et al., 1996). FGF also stimulates proliferation of glial cells after contusive SCI
(Zai et al., 2005). The viability of oligodendrocytes is potentiated by cytokines such as
ciliary neurotrophic factor (CNTF) and leukemia inhibitory factor (LIF) (Kahn and De
Vellis, 1994). In animal models, CNTF and LIF protect against demyelinisation and oli-
godendrocyte apoptosis in autoimmune encephalomyelitis (Butzkueven et al., 2002, Linker
et al., 2002); they both are also detectable in CNS astrocytes (Stockli et al., 1991, Aloisi et
al., 1994), and CNTF is upregulated after cortical lesions (Lee et al., 1997) and ischemia
(Park et al., 2000). During remyelinization, insulin growth factor-1 (IGF-1) is upregulated
in astrocytes (McMorris et al., 1993) and stimulates their proliferation (Tranque et al.,
1992). In the developing optic nerve, IGF-1 acts as a survival factor for oligodendrocyte
progenitor cells and oligodendrocytes (Barres et al., 1992) and is increased after ischemia
(Gluckman et al., 1992).
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The transforming growth factor-?s (TGF-?s) are a family of proteins with di-
versive CNS activities including neuroprotection (Grande, 1997). TGF-?1 activates a hy-
pertrophic response in astrocytes, thereby upregulating GFAP (Laping et al., 1994). Astro-
cytic TGF-?1 increases as a response to other neurotrophins such as NGF, and is further
autoinduced (Lindholm et al., 1990, da Cunha and Vitkovic, 1992, Morganti-Kossmann et
al., 1992). TGF-?1 also induces the synthesis of ECM proteins such as type I collagen, fi-
bronectin, and laminin (Baghdassarian et al., 1993).
4.2.3 Laminin
Fetal sensory neurons with NGF added to the culture medium show the neurite outgrowth
capacity of laminin-1 as a substrate. Laminin-1 shows enhancement in neurite growth
without NGF, and can be suppressed with laminin antibodies (Baron-Van Evercooren et
al., 1982). The axonal regrowth with laminin-1 added to culture wells, when further tested
on neurons removed from different parts of the PNS and CNS, shows sensitive stimulation
of neurite outgrowth (Manthorpe et al., 1983). In the PNS, Schwann cells in contact with
axons produce laminin-1 on their surfaces (Cornbrooks et al., 1983). In the treatment of
PNS injuries, the neurite outgrowth properties of laminin-1 have been used in the form of
grafts implanted into the injury sites. Gel including laminin-1 enhances axonal growth
through the transected sciatic nerve (Madison et al., 1987).
In the CNS, early cultured astrocytes produce laminin-1 (Liesi et al., 1983).
Neurite outgrowth and attachment capacity in neurons from the postnatal rat brain (Liesi et
al., 1984) and hippocampus (Lein et al., 1992) are stimulated by laminin-1. In vivo,
laminin-1 is expressed by astrocytes in the rat olfactory bulb— known for its regenerational
capacity— and in the frog brain where sectioning of the optic tract enhances expression of
laminin-1 during regeneration (Liesi, 1985). Following an optic nerve crush in goldfish,
laminin-1 is upregulated by optic nerve glia, and stimulates regeneration on retinal ex-
plants (Hopkins et al., 1985). Moreover, in the developing chick optic pathway, laminin-1
is expressed before axon growth is initiated and contributes to the pathfinding of the axons
(Cohen et al., 1987). Laminin-1 is upregulated in the rat brain by astrocytes after KA-
induced injury (Liesi et al., 1984), and lesions to the brain (Stichel and Muller, 1994) and
to the spinal cord (Bernstein et al., 1985). In culture, CNS-derived myelin inhibition on
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neurons may be neutralized by laminin-1 (David et al., 1995). In the hippocampus, plas-
min-catalyzed degradation of laminin-1 makes neurons more sensitive to excitotoxic cell
death (Chen and Strickland, 1997).
In rats, expression of ?1 laminin in reactive astrocytes after spinal cord injury
and surrounding the necrotic area after focal cerebral ischemia (Liesi and Kauppila, 2002)
(IV) is interesting because of the theory of the regenerational capacity of ?1 laminin. Using
a model to investigate laminin impact in hippocampal slice cultures, a lesion was made to
the mossy fiber pathway, and results showed that a reduction in ?1 laminin at mRNA level
in this region reduces the normal capacity of axonal regeneration (Grimpe et al., 2002).
This study showed that the BM-independent ?1 laminin is crucial to regeneration of an
axon tract in the mammalian CNS. In addition, ?1 laminin is proposed to maintain the
critical role of the laminin layer in the hippocampus and protect neurons against excito-
toxic cell death (Chen et al., 2003). In the PNS, as well, mutant mice with reduced expres-
sion of ?1 laminin and sciatic nerve damage show impaired peripheral axonal regeneration
(Chen and Strickland, 2003).
4.2.4 KDI peptide
The neurite outgrowth functions of ?1 laminin have been proposed to be carried out by a
decapeptide (RDIAEIIKDI). Nanomolar concentrations of this decapeptide, located in the
C-terminal of the ?1 chain, promote neurite outgrowth in organotypic cultures on both pe-
ripheral and central neurons (Liesi et al., 1989). This RDIAEIIKDI peptide also directs ax-
onal growth in rat embryonic hippocampal neurons in cell culture (Matsuzawa et al., 1998)
and participates in neuronal differentation (Matsuzawa et al., 1996). Using slice prepara-
tions of adult rat neocortex, intracellular recordings demonstrate that the decapeptide of ?1
laminin raises both the input resistance of the neuronal membrane and the excitability of
pyramidal neurons (Hager et al., 1998). The decapeptide of ?1 laminin induces potassium
currents in primary cultured cerebellar neurons, and the smallest peptide derived from it
that is capable of inducing the same electrophysiological properties and supporting neurite
outgrowth is the KDI tripeptide (Liesi et al., 2001). Since the decapeptide is neurotoxic in
high concentrations, and these effects can be inhibited in cell culture by addition of pertus-
sis toxin, an inhibitor of G-protein function, it is possible that the decapeptide of ?1
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laminin can function also through a G-protein receptor-mediated mechanism (Liesi et al.,
2001). In the developing human SC, KDI peptide is localized in the floor plate region
where comissural axon guidance occurs (Wiksten et al., 2003). In matrigel culture systems,
KDI also attracts axonal growth from SC explants (Wiksten et al., 2003). Local infusion of
KDI peptide, shown by use of osmotic mini pumps in transected SC in rats, has also shown
enhancement of neuronal regeneration and has improved the functional recovery after SCI
(Wiksten et al., 2004).
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AIMS OF THE STUDY
The overall purpose of the project was to clarify the role of ?1 laminin and its KDI peptide
in neuronal regeneration and further elucidate the role of laminins in the injured CNS. The
specific aims were:
I To determine the possible regenerational effects of the KDI peptide on neu-
ronal survival and neurite outgrowth in a culture system mimicking challenging envi-
romental factors known to inhibit CNS regeneration.
II To determine whether the KDI peptide can protect hippocampal neurons
against excitotoxic cell death caused by kainic acid.
III To determine the hypothesis of KDI peptide function, through the glutamate
system, at cellular level by investigating glutamate receptors and electrophysiological re-
sponses.
IV To map the temporal and spatial distribution of laminins in the CNS of adult
rats with permanent focal cerebral ischemia.
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MATERIALS AND METHODS
For more specific information on the experimental procedures please see the original pub-
lications (I), (II), (III), and (IV). All experiments were approved by the relevant authorities.
Human CNS tissues (I), (III)
The human CNS tissues were collected with the permission of the donors from aborted 8-
to 10-week-old human fetuses in collaboration with the Maternity Hospital of the Helsinki
University Central Hospital. Adult human spinal cord came from the Neurological Speci-
men Bank (Baltimore, MD, USA).
KDI peptide (I), (II), (III) and Kainic acid (II)
KDI peptide was synthetically manufactured as a C-terminal acid with a 95% purity level
(Multiple Peptide Systems, La Jolla, CA, USA) and dissolved in deionized sterile water to
a concentration of 10 mg/ml, from which it was further diluted to the concentration used.
Kainic acid (Sigma, St. Louis, MO, USA) was diluted to 1mg/ml in 0.9% NaCl, and fur-
ther diluted to the concentrations used.
Human embryonic SC glia cultures (I)
Primary glial cell cultures were obtained by mechanical dissociation of human embryonic
SC and cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, Paisley, Scot-
land) with 10% fetal calf serum (Hyclone, Logan, UT, USA) and antibiotics. The cell lines
were identified by 100% TUJ1 (Sigma) immunostaining, indicating that the glial cells
were precursors of astrocytes; 10 to 20% of these cells were also positive to GFAP
(Sigma) immunostaining, and no oligodendrocyte-like cells were detected, thus indicating
that most of the cells were precursors of astrocytes.
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Experimental culture system I: Glial injury (I)
Human embryonic glial cells were replated on glass coverslips and cultured to confluent
monolayers. The monolayers were injured with a 18-G needle, and the culture medium
was changed to 10% normal adult human serum in DMEM (Gibco). KDI peptide (Multiple
Peptide Systems) was added in different concentrations to the culture medium, and disso-
ciated cells from human embryonic neocortex, retina, and SC were added to the coverslips.
After 72 hrs, the cultures were fixed with 2% paraformaldehyde in PBS (Sigma) for 15
min. Survival of neurons and length of neurites on the injured glial cells was evaluated by
counting TUJ1-positive neurons and their TUJ1-positive neurites. The number of neurons
was counted on ten random fields on six different coverslips. The amount of long neurites
from all neurons was counted from six coverslips in each experimental group. For statisti-
cal evaluation, one-way analysis of variance (ANOVA) was used.
Embryonal bodies of human CNS (I)
Embryonal SC and neocortex containing immature stem cells was mechanically dissoci-
ated and cultured in Neurobasal medium (Gibco) with B27 supplement (Gibco), glutamine,
and antibiotics. Failing to attach to the petri dish surface, the embryonal bodies grew in
aggregates, releasing new bodies and increasing in size.
Experimental culture system II: Myelin inhibition (I)
Adult human SC sections (10 ?m) were cut on slides and placed in sterile Quadriperm
plates (In Vitro Systems and Services, Göttingen, Germany) with DMEM culture medium
(Gibco), 10% human serum, and antibiotics. Various concentrations of KDI peptide (Mul-
tiple Peptide Systems) were added to the culture medium. Embryonal bodies were placed
on top of the white matter of the SC sections and cultured for 10 days before fixation. Im-
munostaining of neurofilament proteins and glial cells identified the neurites and cells of
the embryonal bodies. Evaluation of the neurites growing out from the embryonal bodies
on top of the white matter was done by counting neurites of each slide and was analyzed
with a nonparametric Mann-Whitney test.
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Antibodies for immunocytochemistry (I), (II), (III), (IV)
For immunohistochemical detection of antibodies, various isoforms of laminins were used:
rabbit polyclonal antibodies to identify ?1-5, ?1-3, and ?1-2 laminins (II, IV). Laminin-1
was detected by use of polyclonal antibodies against biochemically purified EHS-tumor
laminin (II, IV). To detect the neurite outgrowth-promoting peptide of ?1 laminin (KDI), a
polyclonal rabbit antibody raised against KLH-coupled (keyhole limpet hemocyanin) 6
amino-acid peptide (EIIKDI) was used (IV). Antibodies pre-absorbed with their respective
peptide antigens or pre-immune sera of each rabbit used for immunizing served as controls
(II, IV). All control experiments were negative.
Mouse monoclonal antibodies against neuron-specific ? tubulin (TUJ1,
Sigma) served to detect neurons, dendrites, and axons (I). TUJ1 also served as a marker for
early glial cells (I). Mouse monoclonal antibodies against the glial fibrillary acidic protein
(GFAP, Sigma) served for detection of astrocytes and radial glial fibers (I, II, IV).
Rabbit polyclonal antibodies against different glutamate subunit proteins
AMPA (GluR1, GluR2/3, GluR4), kainate (GluR5, GluR6/7, KA2), and NMDA (NR1,
NR2A, NR2B) (Upstate, Lake Placid, NY, USA) showed the expression of these glutamate
subunit receptors (III).
Immunocytochemistry on sectioned rat brain (II), (IV)
Brains from decapitated adult male Wistar rats were sectioned. For paraffin sections (II),
the brains were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS, Sigma)
for 12 hrs at +4°C. The brains were then washed in PBS for 48 hrs before being embeded
in paraffin wax. The serial sections were cut in the coronal plane through the hippocampus
and stained with hematoxylin-eosin (II).
For immunocytochemistry of laminins and glial fibrillary acidic protein
(GFAP) in rat brain, the brains were frozen in powdered dry ice: 10 days after stereotaxic
injections (II) or following the variable post-ischemia time periods (IV). The sections were
fixed in 0.4% para-benzoquinine (Fluka, Buchs, Switzerland) in PBS for 15 min at +4°C.
The sections were then rinsed in PBS before dehydration and rehydration in a series of al-
cohols. Fixed sections were incubated overnight in normal goat serum (1:30 dilution in
PBS; Sigma). Antibodies against the various isoforms of laminins were applied, and incu-
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bation was for 24 hrs at +4°C. The sections were then rinsed in PBS and incubated with
fluorescein isothiocyanate-coupled goat antirabbit immunoglobulins (FITC; Cappel, Coch-
ranville, PA, USA) for 1 hr at room temperature (RT). For double-staining, the sections
were incubated further with mouse monoclonal antibodies overnight at +4°C. Mouse
monoclonal antibodies against GFAP served to identify reactive astrocytes. The sections
were rinsed and exposed to goat anti-mouse immunoglobulins coupled to tetramethylrho-
damine isothiocyanate (TRITC; Cappel) for 1 hr at RT. The sections were rinsed in PBS
and mounted in PBS:glycerol (1:1) for microscopic  analysis.
Immunocytochemistry on cultured neurons (I), (III)
The neurons were fixed in 2% paraformaldehyde/PBS for 15 min at RT and permeabilized
with cold (-20°C) methanol for 5 min. In experimental culture system I (I), immunoreac-
tivity for ?-tubulin (TUJ1) served to identify and visualize neurons along with their long
neurites. The antibody was incubated for 1 hr at RT. After being rinsed with PBS, the cul-
tures were exposed to goat anti-mouse immunoglobulins coupled to fluorescein isothiocy-
anate-coupled goat-antirabbit immunoglobulins (FITC; Cappel) for 30 min at RT. The
coverslips were then rinsed and mounted in PBS:glycerol (1:1) (I).
Immunocytochemistry on human embryonic neocortical neurons cultured for
14 to 30 days on a poly-D-lysine substratum (10?g/ml; Collaborative Research, Bedford,
MA, USA) was used to demonstrate the expression of glutamate receptors (IV). After fixa-
tion with 2% paraformaldehyde/PBS the cultures were treated with 0.05% Tween-20/PBS
for 30 min at RT. Incubation with rabbit polyclonal antibodies against proteins represent-
ing different receptor subunits of AMPA (GluR1, GluR2/3, GluR4), kainate (GluR5,
GluR6/7, KA2), and NMDA (NR1, NR2A, NR2B) (Upstate) was done for 1 hr at RT. Af-
ter being rinsed with PBS, the cultures were exposed to goat anti-rabbit immunoglobulins
coupled to FITC (Cappel) for 30 min at RT. The coverslips were then rinsed and mounted
(IV).
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Stereotaxic injections (II)
In adult male Wistar rats anesthetized with 3.5% chloral hydrate (350 mg/kg intraperito-
neally), stereotaxic coordinates were used for the right side of the hippocampus (Paxinos
and Watson 1986). First, an injection of the KDI solution (1?l at 100 or 500 ?g/ml concen-
trations) or NaCl (1?l) was given over a time-period of 5 min and followed by a second
injection of kainic acid (1?l at 1?g/?l, Sigma) or NaCl (1?l). To prevent backflow, a pause
of 5 min occurred after the second injection. The tissue-spreading of the injected solutions
was determined by injections of methylene blue. The animals were decapitated by guillo-
tine and the brains removed. Tissue damage from injected NaCl + kainic acid, KDI + kai-
nic acid, and NaCl + NaCl was determined at the injection site by light microscopy and
evaluated by assigning lesion points depending on extent of damage.
Whole-cell patch-clamp recordings (III)
Human neocortical neuronal cultures were placed under a microscope for patch-clamp re-
cordings. Neurons were continuously superfused with an external solution at RT. During
the recordings, the cells were whole cell-voltage clamped at -60 mV. The drugs were di-
luted in the external solution and applied to the cells with a three-channel stepper motor-
driven fast-application system (Warner Instrument, Hamden, CT, USA). The test drugs,
laminin-1 and laminin peptides, were first preapplied to cells, followed by a coapplication
of the agonists: L-glutamate, concanavalin A (Sigma), SYM 2081, NMDA (Tocris, Avon-
mouth, UK) and test drugs. The current recordings were done with an Axopatch 200B am-
plifier and analyzed with pClamp 8.0 software (Axon Instruments Inc., Foster City, CA,
USA).
Human embryonic kidney cells (HEK 293 cells) were cultured and transfected
with recombinant GluR4 (AMPA) and GluR6 (kainate) receptor subunit cDNA clones in
order to improve kainate current recordings and to compare the AMPA currents measured
in neocortical neurons.
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Focal cerebral ischemia (IV)
All rats were adult male Wistar rats anesthetized with ketamine hydrochloride and mede-
tomidine hydrochloride. Based on the suture occlusion model (Takano et al., 1997), per-
manent focal cerebral damage was induced. Through a ventral midline incision, the right
common carotid artery (CCA) and the right external carotid artery were uncovered, and a
4-0 nylon monofilament suture (Ethilon Nylon Suture, Ethicon Inc., Somerville, NJ, USA)
with a coated silicone tip (Bayer, Leverkusen, Germany) was inserted into the right CCA
via an arteriectomy approximately 3 mm below the right carotid bifurcation. Advancing
the suture along the internal carotid artery approximately 17 mm above the carotid bifurca-
tion allowed it to be lodged into the anterior cerebral artery, occluding the orifice of the
middle cerebral artery and the posterior communicating artery. The control animals (sham
operated) were exposed to the same procedures, except that the suture was inserted only 10
mm above the carotid bifurcation and withdrawn one minute later. The animals with per-
manent middle cerebral artery occlusion (MCAO) were divided into 1-, 2-, 3-, 7-, 14-, and
28-day groups according to their post-ischemic time-periods before cardiac perfusion. Fol-
lowing the various post-ischemic periods, the rats received 120 mg of sodium pentobarbi-
tal (Mebunat, Orion Company, Finland), and cardiovascular perfusion was executed with
200 ml of ice-cold 0.9% saline (Liu et al., 2001). The brains were removed, frozen in fine
dry ice, and stored at -70°C for further investigation.
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RESULTS
1. Effects of KDI peptide in experimental culture systems (Study I)
An experimental culture system (I) was designed to test effects of the KDI peptide on neu-
rons in an environment with damaged glial cells. It was tested on neurons from human em-
bryonic retina, spinal cord (SC), and neocortex, all plated on top of injured SC glial cells.
Neurons plated without KDI peptide on the damaged glial cells showed poor neurite out-
growth. Adding KDI peptide to the culture medium in low concentrations of 0.035 to 1.0
µg/ml improved both neurite outgrowth and neuron survival. Neurons of SC origin pre-
ferred lower concentrations of KDI peptide (0.035-0.1 µg/ml) in terms of long neurites and
number of viable neurons in comparison to neocortical neurons requiring higher KDI con-
centrations (0.1-1.0 µg/ml). Long neurites and survival of retinal neurons showed the best
effect at a KDI concentration 0.1 µg/ml.
An experimental culture system (II) was designed to test the effect of KDI
peptide on axonal growth on damaged myelin sheets. Its effect was tested by using embry-
onal bodies planted on top of sectioned SC. The embryonal bodies were placed on the
white matter of the spinal cord and were thereby in direct contact with the underlying
cross-sectioned myelin sheets known to prevent neurite regeneration. Neurites were visible
growing inside the embryonal bodies but were unable to grow on top of the CNS myelin.
Addition of KDI peptide (5-10 µg/ml) to the culture medium enabled outgrowth of neurites
on top of the SC white matter, with long neurites extending from the embryonal bodies
visible.
2. Protection against KA-induced hippocampal damage (Study II)
Hippocampal damage in rats resulted from stereotaxic injections of KA, and the effects of
pre-injected KDI peptide on this damage showed that the unilateral injection of KA caused
severe tissue damage visualized in hematoxylin-eosin (HE)-stained brain sections. The tis-
sue damage left cavities around the injection site of the hippocampus and neocortex, and
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sections stained for GFAP showed gliosis around the areas of destruction. Animals treated
with pre-injections of KDI peptide (100 µg/ml) showed, however, less tissue damage
around the hippocampal areas than in KA-injected animals but was unable to protect the
neocortical areas. A higher dose of KDI peptide (500 µg/ml) was able to protect the hippo-
campal and neocortical areas, so that destroyed tissue appeared only around the immediate
area of injection. Reactive gliosis was visible in the ipsilateral hippocampal and neocorti-
cal areas in animals treated with the higher dose of KDI before KA-induced injury. Injec-
tions of NaCl + NaCl resulted in increased gliosis around the injection track. Sections
stained with GFAP showed more gliosis in KDI peptide (500 µg/ml) + KA-treated animals
than did KDI peptide (500 µg/ml) + NaCl or NaCl + NaCl-injected animals. Tissue dam-
age was quantified by lesion points at the injection site by visual scoring of the extent of
the injury, and showed that preinjection of KDI peptide (500 µg/ml) was able to protect
both hippocampal and neocortical tissue from KA-induced damage, even though the tissue
at the immediate injection site showed signs of injury.
Kainic acid injections caused neocortical and hippocampal tissue degradation
also on the contralateral side of the brain sections. Expression of ?1 laminin on the contra-
lateral side of the hippocampus 10 days after NaCl + kainic acid injections showed reactive
astrocytes in the CA1-layer but no immunoreactive neurons. Animals injected with KDI
peptide (500 µg/ml) + KA into the CA1-layer of the ipsilateral hippocampus showed ?1
laminin-immunopositive neurons protecting them from KA damage. At the very site of the
injection, the animals treated with KDI peptide (500 µg/ml) had a gap area lacking ?1
laminin-positive neurons and showed only immunoreactive glial fibers. Similarly, a nega-
tive gap in immunoreactivity appeared in the expression of laminin-1 in the CA1 layer of
the hippocampus. Laminin-1 expression showed an increase at the injection area of the
neocortex, and accumulation of laminin-1 punctate deposits were visible, indicating
laminin-1 degradation. These laminin-1 deposits were absent from the KDI-treated brain
sections.
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3. Glutamate receptor inhibition by KDI peptide (Study III)
KA takes part in excitotoxic cell death through glutamate receptors. Since KDI peptide in-
jection was able to protect against KA-induced tissue damage in rat brain (II), we studied
the possible interactions of KDI with glutamate receptor function by using immunocyto-
chemistry and patch clamp recording.
Immunocytochemistry on human embryonic neocortical neurons showed ex-
pression of several different glutamate receptor proteins. AMPA receptor subunit GluR1
expression was strongest in cell bodies; GluR2/3 expression occurred along neurites and
cell bodies; and GluR4 immunoreactivity was homogeneous along both neurites and cell
bodies. Kainate subunit immunoreactivity was expressed in GluR5 as punctate deposits
along the neurites; GluR6/7 was detected along the more mature-looking pyramidal neu-
rons; and KA2 receptor immunoreactivity along both neurites and cell bodies. NMDA re-
ceptor subunit immunoreactivity was seen in NR1 as a patchy expression along neurites,
and both NR2A and NR2B showed weaker expression, mainly in the cell bodies of the
neurons. Therefore, NMDA heterodimeric receptor proteins NR1/NR2A and NR1/NR2B
were expressed by the cultured neurons.
Application of glutamate to the cultured neocortical neurons under conditions
that inhibit NMDA receptors produced a fast desensitizing current that was mediated pri-
marily through AMPA receptors, since application of a selective kainate receptor agonist
(SYM 2081 together with concavalin A) produced only a small, insignificant current. Im-
munocytochemically, kainate-receptor subunits were evident, but here, neocortical neurons
failed to express functioning kainate receptor currents. Inhibition of the AMPA current by
pre- and co-application of KDI peptide (0.1-10 µg/ml) was detected as dose-dependent,
washable, and reproducible. In comparison to laminin-1, and the decapeptide of ?1 laminin
(RDIAEIIKDI), which also showed effective AMPA receptor inhibition, the KDI peptide
was more efficient and showed a higher precentage of inhibition. Peptides from ?1 laminin
(CDPGYIGSR) and ?2 laminin (LRE) did not affect the AMPA receptor currents. KDI
peptide inhibition of AMPA receptor currents was seen as dose-dependent, and a concen-
tration of 0.1 µg/ml showed 50% inhibition (IC50). Half the maximal effective concentra-
tion (EC50) of glutamate yielded values of 2.5 and 1.9 mM in the absence and presence of
KDI peptide, indicating the noncompetitive nature of this inhibition. The KDI peptide pre-
45
application time needed for maximal inhibition was measured as short (62 ± 22 msec), and
coapplication with glutamate produced lower inhibition of AMPA currents.
NMDA receptor currents measured from neocortical cell cultures were also
inhibited by KDI peptide (0.1-10 µg/ml) by 25 to 50%.
Kainate receptor currents were undetectable in human neocortical neurons, al-
though immunocytochemistry showed their expression. Human embryonic kidney cells
(HEK 293 cells) transfected with the recombinant GluR6 receptor subunit were used to
study the effects of the KDI peptide on kainate receptor currents. The kainate currents
were sensitive to KDI peptide inhibition, showing a IC50 at 0.1 µg/ml and almost a total
inhibition at 10 µg/ml. HEK cells transfected with GluR4 AMPA receptors and human
neocortical neurons were equally sensitive to the KDI peptide.
4. Distribution of laminins in focal cerebral ischemia (Study IV)
Permanent MCAO was performed in adult rats in order to map the temporal and spatial
expression of laminins associated with ischemic brain damage. All animals with right
MCAO had left-sided hemiparesis after the operation in comparison to sham-operated rats,
which showed no neurologic deficits.
Laminin-1 was expressed in sham-operated rats in vascular basement mem-
brane structures symmetrically on both sides of the brain hemispheres; 24 h after ischemia
laminin-1 was expressed in neurons and vascular basement membrane structures of the
ischemic region, and 2 to 3 days after ischemia the vascular basement membranes ex-
pressed laminin-1 but with no immunoreactive neurons visible. Seven days after MCAO,
however, a large necrosis area was detectable, with laminin-1-positive basement structures
and scar-forming extracellular matrix (ECM). And 14 and 28 days after ischemic brain
damage, the laminin-1-positive necrotic area was clearly visible as immunoreactive matrix
and punctate deposition.
In the ventrolateral parts of the brain, ?1 laminin was already expressed 24 h
after MCAO in reactive astrocytes surrounding the ischemic area, and at 2 to 3 days a ?1
laminin-positive belt of glial cells formed. At 24 h, immunoreactive astrocytes appeared
inside the ischemic regions, and also ?1 laminin-positive neuronal cell bodies and den-
drites of pyramidal neurons were detectable. At 7, 14, and 28 days, reactive astrocytes
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heavily expressing ?1 laminin surrounded the necrotic area, separating it from the rest of
the brain. Here, no neuronal ?1 laminin immunoreactivity was detectable. In the contralat-
eral intact brain hemisphere, normal, mainly neuronal expression of ?1 laminin was evi-
dent and was similar to that in the sham-operated rats.
KDI peptide was expressed, in a similar manner to that of ?1 laminin, in-
tensely in glial cells between the intact brain and the ischemic regions. Additionally, KDI
immunoreactivity was visible along the major neuronal pathways such as the corpus callo-
sum and in the fiber areas close to the ischemic regions.
Laminins ?1, ?2, ?5, and ?2 were induced in reactive astrocytes surrounding
the ischemic infarct areas, differing in their expression patterns and from the expression of
?1 laminin. Three days after infarction, expression of laminins ?1 and ?5 was induced in
dendrites of the pyramidal cells inside the ischemic area in comparison to the contralateral
side, which lacked any such immunoreactivity.
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DISCUSSION
Functional properties of the KDI peptide
The exact molecular mechanisms of the neuroprotective effects of KDI peptide remain un-
known even though many studies elucidate its neuroprotective effects, and it seems fair to
claim that the KDI peptide probably has several mechanisms of action. Its neuroprotective
potential against CNS trauma, SC injury (Wiksten et al., 2004), and injuries induced by
neurotoxins (II) (Väänänen et al., 2006), in concert with its promotion of neurite outgrowth
and neuronal survival (I), indicates different functional pathways. Evidence that the KDI
peptide protects hippocampal tissue from KA, that it takes part in excitotoxic cell death
through glutamate receptors, points toward a possible interaction between the glutamate
system and the KDI peptide (II). Indeed, patch clamp recordings show that the KDI pep-
tide is capable of inhibiting the ionotrophic glutamate receptors NMDA, AMPA, and
kainate in a dose-dependent and non-competitive manner, with a 50% inhibition of the
NMDA receptors and almost a complete inhibition of kainate and AMPA receptors (III).
Experiments defining the shortest active sequence of the decapeptide RDI-
AEIIKDI showed, by patch clamp recordings, that the KDI peptide induces potassium cur-
rents through a G-protein coupled mechanism in rat cerebellar neurons (Liesi et al., 2001).
The outward rectifying currents may enhance neuronal survival by inhibiting repeated de-
polarizations and reducing Ca2+ influx into the neurons. The decapeptide RDIAEIIKDI has
also been shown to have a dual neurotoxic/neurotrophic role: When it is applied in high
amounts to neurons, a neurotoxic effect results, a neurotoxic effect that can be attenuated
by pertussis toxin, which inhibits the potassium current caused by the decapeptide (Liesi et
al., 2001). When the concentration of the KDI peptide increases from the optimal concen-
tration inducing neuronal survival and neurite outgrowth, interestingly, a reduction in these
neuroregenerative functions also is noticeable (I).
Through integrin ?1 signalling and activation of the PI3-kinase/Akt pathway,
laminin enhances resistance to glutamate-induced apoptosis in embryonic hippocampal
neurons (Gary and Mattson, 2001). Intriguingly, a peptide (EIKLLIS) derived from the ?
chain of laminin also protects hippocampal neurons from apoptosis induced by glutamate,
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and enhances Akt activity in a similar manner (Gary et al., 2003). A recent report suggests
that intracellular pathways stimulating neuronal survival and neurite outgrowth in DRG
neurons (PI3-kinase/Akt- and MEK/MAPK-pathway) are induced by simultaneous stimu-
lation of both laminin and NGF, suggesting that collaboration of integrin and neurothro-
phin signalling is essential in DRG neuron regeneration (Tucker et al., 2008). Concerning
KDI function, when discussing integrin signalling and laminin binding, what should be
noted is that even though the KDI peptide shows laminin-like effects on neurite outgrowth,
laminins are not known to bind integrins via the C terminus of ?1 laminin. It is therefore
possible that KDI peptide function may also involve laminin receptor stimulation. More
importantly, due to the size and specific functions of the KDI peptide and other laminin-
derived peptides, they should be investigated according to their own specific functions and
not be considered identical in function to the large laminin-1 molecule. In contrast, regard-
ing functions of the laminin protein, the active peptides derived from laminin-1 provide
important information.
These findings supporting the neurotrophic properties of the KDI peptide indi-
cate involvement of a more classical receptor stimulation. Laminin receptors, 67kDa, ?-
dystroglycan, and integrins may be potential targets for activation involving secondary
messenger systems and thereby may take part in axonal outgrowth and neural regeneration.
Laminin and the KDI peptide in neural regeneration
Laminin-1 is known to be a promoter of neuritic regeneration (Manthorpe et al., 1983). Its
regenerative function has been mapped in the C-terminus of ?1 laminin to the decapeptide
RDIAEIIKDI (Liesi et al., 1989) and from there, more specifically to the KDI tripeptide
(Liesi et al., 2001). It has been proposed that ?1 laminin plays an important role in the
guidance of commissural axons in the developing human spinal cord (Wiksten et al.,
2003). In the lesioned postnatal rat, the hippocampal mossy fiber, an inhibition of ?1
laminin, mRNA translation leads to a clear reduction in regeneration, and when inhibition
ceases, regeneration capacity is restored (Grimpe et al., 2002). Matrigel culture experi-
ments show that axons from dorsal embryonic spinal cord prefer to grow axons towards
the KDI peptide-containing matrix (Wiksten et al., 2003) indicating that the KDI peptide
may serve as a chemoattractant for these neurons. Since laminin-1 overrides myelin-
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derived inhibitory effects on neurite outgrowth (David et al., 1995), we tested the effects of
the KDI peptide in a environment hostile toward neuronal survival and neurite outgrowth.
Environmental factors that prevent spinal cord regeneration after injury are
mainly the formation of a glial scar and myelin-derived inhibition (see 4.1.1 and 4.1.2) and
therefore serve as an example in the experimental culture settings (I).
In two different experimental culture systems mimicking spinal cord injury,
the KDI peptide attenuated the glia-derived and myelin-derived inhibitory signals and pro-
vided a better substrate for neuronal survival and neurite outgrowth. Both viability and
neuronal outgrowth were improved by addition of KDI peptide to the culture medium, re-
gardless of the CNS origin of the cultured neurons used. Neurons derived from human em-
bryonic spinal cord, neocortex, and retina reacted somewhat differently to the KDI peptide
applied. Spinal cord neurons preferred a lower concentration of KDI peptide than did neo-
cortical neurons for optimal neurite outgrowth and survival (I). This fact indicates that ap-
plication of KDI in vitro supports neurons to overcome inhibition and grow axons on ad-
verse surfaces such as injured glial cells and the white matter of the spinal cord (I).
The in vitro results supporting the KDI peptide as a regenerative factor in CNS
injury led to in vivo experiments on spinal cord injury and kainic-acid induced injury in
rats. Following complete transection of rat spinal cord, KDI peptide was applied directly to
the area of injury through osmotic mini-pumps. The KDI-treated animals showed im-
provement in motor-scoring and were able to support their weight using their hind legs, in
comparison to the paralyzed control animals. Immunohistochemistry showed improvement
in regeneration of the damaged neural tracts (Wiksten et al., 2004). Aside from its possible
stimulating effects on axonal regeneration, the KDI peptide may enhance regeneration by
affecting inhibitory enviromental factors and thereby supporting neuronal survival and ax-
onal growth. Interestingly, in KDI-treated spinal cord injury, both scar- and cyst-formation
was reduced (Wiksten et al., 2004), possibly promoting the ability of axons to overcome
inhibition and giving neurons a more beneficial environment in which to regenerate.
Study 1 used an in vitro model to mimic the major inhibitory signals against
regeneration caused by SCI. Since no established in vitro model for this purpose was
available, we developed a novel model of our own, where myelin inhibitory molecules
primarily produced by oligodendrocytes were represented in one experimental setting and
the astroglial glial scar in another. When planning in vitro experiments aiming to test SCI,
many aspects should be taken into consideration since the cellular and molecular incidents
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following CNS damage in vivo are numerous and could hardly all be tested simultane-
ously in one single experimental setting. Here in Study 1, our goal was to test the effect of
the KDI peptide added to the culture media as the external source, and we designed the in
vitro experiment to test its effect on neuronal viability and axonal growth on damaged as-
troglia and myelin sheets.
Regeneration might also be stimulated by reducing the molecular constituents
of the glial scar, as seen in Study II. Reactive gliosis (II) and cyst formation (Wiksten et
al., 2004) was reduced by KDI peptide, but this claim should be considered speculative
since our experiments do not provide any such direct evidence.
The KDI peptide and CNS protection
The protection provided by the KDI peptide against hippocampal injections of kainic acid
is interesting. Since KA, a glutamate analogue, is known to mediate excitotoxicity through
glutamate receptors, the protective effects of KDI against this neurotoxin indicates a link
between the laminins and the glutamate system. Hippocampal neurons from the CA1-CA3
region exert a high concentration of ionotropic glutamate receptors and are particularly
vulnerable to KA (Ben-Ari, 1985). KA has also been associated with neurodegenerative
disorders (Fahn and Sulzer, 2004), CNS trauma (Arundine and Tymianski, 2004), and neu-
ronal death (Ben-Ari and Cossart, 2000).
A pre-injection of KDI peptide (500 µg/ml) was able to protect the hippocam-
pal tissue against KA injections, leaving only a small destroyed area around the exact point
of the injection. Animals pre-treated with NaCl injections showed severe destruction of
hippocampal and neocortical tissue due to KA neurotoxic injections (II). Intact hippocam-
pal neurons express ?1 laminin (Hager et al., 1998), and this expression is reduced by KA
(Indyk et al., 2003). Similarly, in our experiments following NaCl + KA injections, expres-
sion of ?1 laminin in the contralateral hippocampus showed reactive astrocytes in the CA1-
layer but no immunoreactive neurons. At the very site of injection, the animals treated with
KDI peptide (500 µg/ml) had a gap area lacking ?1 laminin-positive neurons, and showing
only immunoreactive glial fibers (II).
Tissue plasminogen activator (tPA) and its substrate plasminogen are associ-
ated with excitotoxic neuronal degeneration in the hippocampus. Deficiency of tPA or
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plasminogen induces resistance against neuronal death caused by KA (Tsirka et al., 1997).
Extracellular plasmin generation that could promote neuronal death is interesting to exam-
ine from a substrate point of view, since laminin cleavage may promote neuronal degen-
eration. Interestingly, laminin is normally expressed in the hippocampus but cannot be de-
tected after KA injections, and its disappearance occurs just before neuronal cell death oc-
curs (Chen and Strickland, 1997). Neuronal degeneration can be inhibited by tPA-
deficiency or infusion of a plasmin inhibitor that also inhibits laminin degradation; in con-
trast, excitotoxic sensitivity can be restored in tPA-deficient mice by infusion of anti-
laminin antibodies (Chen and Strickland, 1997). Disruption of the laminin hippocampal
matrix by infusion of soluble laminin-1 or anti-?1 laminin antibodies sensitizes neurons to
KA-induced cell death (Chen et al., 2003). These results further establish the importance of
the laminin matrix and ?1 laminin in regard to excitotoxic cell death, degradation of
laminin, and neuronal survival. Fragments of degraded laminin, due to plasmin induction
after KA injections, may have functional effects on surrounding cells. Naturally, of interest
here would be a hypothetical KDI peptide that could be detected as a peptide sequence fol-
lowing degradation of laminin. Since KA injection induces laminin degradation and neu-
ronal death, the protective effect of the KDI peptide is not liberated, possibly because of
either excessive proteolytic degradation or of incomplete fragmentation.
Following injections of the neurotoxin 6-hydroxy-dopamine (6-OHDA) to the
rat substantia nigra (SN), the KDI peptide has also shown protective effects on dopaminer-
gic neurons (Väänänen et al., 2006). 6-OHDA is a dopamine analogue that forms reactive
oxygen species inhibiting the mitochondrial electron transfer chain that leads to dopa-
minergic neuronal death and neuronal tissue degeneration (Schober, 2004). This neuro-
toxin is used to induce PD in rodents (Schober, 2004), but through its mechanism of ac-
tion, it can also be viewed as an inductor of oxidative stress. Therefore, the protective ef-
fect of the KDI peptide against 6-OHDA-induced neurotoxicity and oxidative stress pro-
vides a new perspective on KDI neuronal protection that still needs to be further eluci-
dated. One possible mechanism of protection may be through KDI inhibition of the gluta-
mate receptors (III), since simultaneous glutamate excitation and 6-OHDA dopamine re-
ceptor activation may lead to the neuronal overexcitation, causing neuronal death.
In Study II, the damage caused by KA is dramatic and if applied in lower
amounts the neurotoxic solution could test other more neurotropic effects of laminins and
KDI because of the less damaging environment. Since other possible molecular pathways
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of the KDI peptide remain to be revealed, a less damaging environment could be of value
here. However, we preferred to use high doses in order to reach the “proof of principle”
point. The ability to protect neurons against oxidative stress caused by 6-OHDA is shared
with neurotrophins, and the mechanism remains unclear. Moreover, the resistance against
KA-induced neurotoxicity in tPA-deficient mice and their unaffected laminin degradation
calls for further studies that could elucidate other molecular mechanisms that stimulate
neuronal viability.
The neuroprotective potential of the KDI peptide is strengthened by findings
regarding its ability to inhibit ionotrophic glutamate receptors. The application of KDI
peptide to neocortical neurons has shown in patch clamp recordings almost a complete in-
hibition of AMPA and kainate receptors and a 50% inhibition of NMDA receptors (III),
providing evidence for a direct interaction between the KDI peptide and the glutamate sys-
tem. The receptor inhibition was non-competitive and dose-dependent. Both laminin-1 and
the decapeptide RDAEIIKDI of ?1 laminin also showed an inhibition of AMPA receptor
currents but were less efficient than the KDI peptide (III). The acid form of the decapep-
tide of ?1 laminin and of KDI peptide is each a more efficient antagonist of glutamate re-
ceptors then is the amide form of each (III), indicating that they would be effective even if
cleaved by proteolysis from the laminin-1 molecule.
These results indicate that a matrix protein or its fragments cannot only medi-
ate its functions indirectly through cell-matrix signaling cascades but can interact directly
with neurons through glutamate receptors. To the best of our knowledge, no previous stud-
ies have shown such direct electrophysiological receptor interaction, even though laminin
has been shown to play a role in inwardly rectifying potassium channel aggregation in hip-
pocampal cultures (Guadagno and Moukhles, 2004) and in direct binding to voltage-gated
calcium channels in mouse motor neurons (Nishimune et al., 2004).
The induced glial cell expression of laminin-1 (Liesi et al., 1984, Bernstein et
al., 1985) and ?1 laminin in pathological conditions such as SC trauma (Liesi and Kaup-
pila, 2002), ischemic stroke (IV), or AD (Palu and Liesi, 2002) may have a protective ef-
fect on their surrounding neurons even though insufficient for neuronal tissue survival.
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Laminins in ischemic stroke
Study of laminins in an experimental stroke model revealed that laminin-1, ?1 laminin, and
its KDI tripeptide were expressed in reactive astrocytes in the transitional zone between
the ischemic regions of necrosis and the rest of the brain. The reactive astrocytes also ex-
pressed ?1, ?2, ?5, ?1, ?3, and ?2 laminin, but only ?1 laminin appeared visible in these
cells specifically isolating the ischemic region as early as 24 h after stroke. Persistent in the
actual infarct area, only laminin-1 was expressed 28 days after ischemic insult, whereas the
other laminin subtypes were detected then mainly in glial cells in the vicinity of the infarc-
tion. Due to their differing spatial and temporal expression patterns, laminin-1 and ?1
laminin are interesting when discussing the involvement of laminins in the pathophysiol-
ogy of stroke.
Expression of ?1 laminin and the KDI peptide by reactive astrocytes at the
boundary of the ischemic brain region may be a protective measure or an epiphenomenon.
However, since laminin-1 and ?1 laminin induction in glial cells occurs following various
mechanical and chemical insults to the brain (Liesi et al., 1984)(II)(Wiksten et al., 2004),
the protective hypothesis is the primary option. In this sense, what is noticeable is that in
regenerating CNS tissues such as the mammalian olfactory bulb, astrocytes express
laminin-1 (Liesi, 1985). The possible protective expression of ?1 laminin and KDI peptide
following ischemic brain damage is supported by evidence that in rats the KDI peptide
protects against mechanical SCI (Wiksten et al., 2004) and reduces neurotoxic damage
caused by the glutamate analogue KA (II). Since the KDI peptide is an inhibitor of gluta-
mate receptors and non-competitively inhibits the AMPA receptor, it may improve neu-
ronal survival in many different CNS injury types (III). Excitotoxic brain damage is the
major common pathway of neuronal damage in many types of CNS injury and a major
mechanism of neuronal degeneration following ischemic stroke. By improving neuronal
regeneration and supporting neuronal survival following excitotoxic insults, the inductive
expression of ?1 laminin and its KDI peptide may strengthen repair mechanisms in the
brain after cerebral ischemic damage. A study by Yepes and colleagues showed that after
focal ischemic brain damage, application of neuroserpin for preservation of laminin, pri-
marily in neurons within the CNS, reduced infarct volume and apoptosis. That immunohis-
tochemistry revealed inhibition of proteolysis of laminin in basement membranes supports
the hypothesis of the protective role of laminin in a stroke model (Yepes et al., 2000). In
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contrast, inhibition of the expression of laminins can hamper the brain’s regenerative ca-
pacity and should be avoided after cerebral injuries. A study by Gu and colleagues showed,
in a mouse focal cerebral ischemia model, that matrix metalloproteinase-9 degrades
laminin, leading to induction of neuronal apoptosis. Blocking of matrix metalloproteinase-
9 activity with a specific thiarine gelatinase inhibitor SB-3CT, and thereby blocking
laminin cleavage, reduces neuronal apoptosis (Gu et al., 2005), suggesting that laminins
may possess anti-apoptotic properties.
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SUMMARY AND CONCLUSIONS
The KDI peptide is a potentially neuroregenerative and neuroprotective peptide derived
from laminin-1. The purpose of this study was to clarify the role of ?1 laminin and its KDI
peptide in neuronal regeneration and further elucidate the role of laminins in the injured
CNS. The in vitro studies presented here suggest that the KDI peptide stimulates neurite
outgrowth and neuronal survival. When KDI peptide is added to their culture media, hu-
man embryonal SC, neocortical, and retinal neurons cultured in a hostile environment
benefit in viability and neurite outgrowth. Neurons cultured on injured glial cells and on
the white matter of sectioned SC are able to grow long neurites in the presence of KDI
peptide. That the KDI peptide protects against hippocampal tissue damage caused by local
injections of KA in vivo supports the in vitro results and indicates that the KDI peptide can
protect against excitotoxic insults. To expand this hypothesis, our electrophysiological ex-
periments interestingly show that the KDI peptide inhibits glutamate receptors in a non-
competitive and dose-dependent manner with almost a complete inhibition of AMPA and
kainate currents and a partial inhibition of NMDA receptor currents. Finally, in an experi-
mental ischemic stroke model, we showed that laminin-1, ?1-laminin, and its KDI peptide
are expressed in reactive astrocytes surrounding the ischemic regions, suggesting their in-
volvement in the pathophysiology of this devastating disease.
Further experiments testing the protective effects of the KDI peptide in other
neurodegenerative disorders would clarify its possible therapeutic potential. For example,
testing the hypothesis of its potential involvement in cerebral stroke requires more exten-
sive studies involving application of KDI peptide.
Exciting questions should be elucidated in the future involving the role of the
laminins in maintaining the BBB: Do laminins stimulate neurogenesis in the dentate gyrus
and the subventricular zone? How do laminins co-localize with newly formed neurons, and
do they participate in forming pathways for neurons to migrate to regions of destruction?
Therapeutically, the KDI peptide may provide a new tool for neuronal regen-
eration and support the viability of neurons in degenerative CNS diseases. Our animal and
cellular experiments show that if used at therapeutic concentrations, the KDI peptide is not
only effective in regenerating and protecting the CNS but is also unlikely to produce overt
adverse effects. A better understanding of KDI as a clinical therapy in treating CNS dis-
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eases calls for more research. In addition, investigating the mechanisms at cellular and mo-
lecular levels through which the KDI peptide may support neuronal viability and protect
against injury is vital for its development towards a therapeutic tool. In today’s research,
many successful biochemical strategies against neuronal death are emerging, and applica-
tion of the KDI peptide together with other therapies could in fact aid in the struggle for
neuroprotection and neuronal regeneration.
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